134 related articles for article (PubMed ID: 25800116)
1. Synthesis and optimization of picolinamide derivatives as a novel class of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors.
Ryu JH; Kim S; Lee JA; Han HY; Son HJ; Lee HJ; Kim YH; Kim JS; Park HG
Bioorg Med Chem Lett; 2015 Apr; 25(8):1679-1683. PubMed ID: 25800116
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of picolinamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Ryu JH; Kim S; Han HY; Son HJ; Lee HJ; Shin YA; Kim JS; Park HG
Bioorg Med Chem Lett; 2015 Feb; 25(3):695-700. PubMed ID: 25529735
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).
Ryu JH; Lee JA; Kim S; Shin YA; Yang J; Han HY; Son HJ; Kim YH; Sa JH; Kim JS; Lee J; Lee J; Park HG
J Med Chem; 2016 Nov; 59(22):10176-10189. PubMed ID: 27798827
[TBL] [Abstract][Full Text] [Related]
4. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of (R)-1-arylsulfonylpiperidine-2-carboxamides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Xia G; Liu L; Liu H; Yu J; Xu Z; Chen Q; Ma C; Li P; Xiong B; Liu X; Shen J
ChemMedChem; 2013 Apr; 8(4):577-81. PubMed ID: 23471829
[TBL] [Abstract][Full Text] [Related]
6. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors.
Sun D; Wang Z; Caille S; DeGraffenreid M; Gonzalez-Lopez de Turiso F; Hungate R; Jaen JC; Jiang B; Julian LD; Kelly R; McMinn DL; Kaizerman J; Rew Y; Sudom A; Tu H; Ursu S; Walker N; Willcockson M; Yan X; Ye Q; Powers JP
Bioorg Med Chem Lett; 2011 Jan; 21(1):405-10. PubMed ID: 21093258
[TBL] [Abstract][Full Text] [Related]
8. 4-(Phenylsulfonamidomethyl)benzamides as potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 with efficacy in diabetic ob/ob mice.
Zhang X; Zhou Z; Yang H; Chen J; Feng Y; Du L; Leng Y; Shen J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4455-8. PubMed ID: 19564108
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.
Julian LD; Wang Z; Bostick T; Caille S; Choi R; DeGraffenreid M; Di Y; He X; Hungate RW; Jaen JC; Liu J; Monshouwer M; McMinn D; Rew Y; Sudom A; Sun D; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
J Med Chem; 2008 Jul; 51(13):3953-60. PubMed ID: 18553955
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260
[TBL] [Abstract][Full Text] [Related]
11. 3-Amino-N-adamantyl-3-methylbutanamide derivatives as 11β-hydroxysteroid dehydrogenase 1 inhibitor.
Lee Y; Shin YJ; Ahn SK
Bioorg Med Chem Lett; 2014 Mar; 24(5):1421-5. PubMed ID: 24507919
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Biological Evaluation of Potent and Orally Active Human 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Type 2 Diabetes Mellitus.
Koike T; Shiraki R; Sasuga D; Hosaka M; Kawano T; Fukudome H; Kurosawa K; Moritomo A; Mimasu S; Ishii H; Yoshimura S
Chem Pharm Bull (Tokyo); 2019; 67(8):824-838. PubMed ID: 31366832
[TBL] [Abstract][Full Text] [Related]
13. The synthesis and SAR of novel diarylsulfone 11β-HSD1 inhibitors.
Yan X; Wang Z; Sudom A; Cardozo M; DeGraffenreid M; Di Y; Fan P; He X; Jaen JC; Labelle M; Liu J; Ma J; McMinn D; Miao S; Sun D; Tang L; Tu H; Ursu S; Walker N; Ye Q; Powers JP
Bioorg Med Chem Lett; 2010 Dec; 20(23):7071-5. PubMed ID: 20971000
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of piperidine urea derivatives as efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in diabetic ob/ob mice.
Zhang L; Chen J; Ning M; Zou Q; Leng Y; Shen J
Bioorg Med Chem Lett; 2012 Apr; 22(8):2748-52. PubMed ID: 22440625
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel curcumin analogues for inhibition of 11β-hydroxysteroid dehydrogenase type 1 with anti-diabetic properties.
Yuan X; Li H; Bai H; Su Z; Xiang Q; Wang C; Zhao B; Zhang Y; Zhang Q; Chu Y; Huang Y
Eur J Med Chem; 2014 Apr; 77():223-30. PubMed ID: 24642565
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Ye XY; Yoon D; Chen SY; Nayeem A; Golla R; Seethala R; Wang M; Harper T; Sleczka BG; Apedo A; Li YX; He B; Kirby M; Gordon DA; Robl JA
Bioorg Med Chem Lett; 2014 Jan; 24(2):654-60. PubMed ID: 24360604
[TBL] [Abstract][Full Text] [Related]
17. Discovery and structure-activity relationships of ent-Kaurene diterpenoids as potent and selective 11β-HSD1 inhibitors: potential impact in diabetes.
Deng X; Shen Y; Yang J; He J; Zhao Y; Peng LY; Leng Y; Zhao QS
Eur J Med Chem; 2013 Jul; 65():403-14. PubMed ID: 23747808
[TBL] [Abstract][Full Text] [Related]
18. The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors.
Cheng H; Hoffman J; Le P; Nair SK; Cripps S; Matthews J; Smith C; Yang M; Kupchinsky S; Dress K; Edwards M; Cole B; Walters E; Loh C; Ermolieff J; Fanjul A; Bhat GB; Herrera J; Pauly T; Hosea N; Paderes G; Rejto P
Bioorg Med Chem Lett; 2010 May; 20(9):2897-902. PubMed ID: 20363126
[TBL] [Abstract][Full Text] [Related]
19. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice.
Park SB; Jung WH; Kang NS; Park JS; Bae GH; Kim HY; Rhee SD; Kang SK; Ahn JH; Jeong HG; Kim KY
Eur J Pharmacol; 2013 Dec; 721(1-3):70-9. PubMed ID: 24135201
[TBL] [Abstract][Full Text] [Related]
20. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
Hale C; Véniant M; Wang Z; Chen M; McCormick J; Cupples R; Hickman D; Min X; Sudom A; Xu H; Matsumoto G; Fotsch C; St Jean DJ; Wang M
Chem Biol Drug Des; 2008 Jan; 71(1):36-44. PubMed ID: 18069989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
